Actualités
Séminaires

Professeur Tadashi Watabe, MD, PhD

Osaka University, Japon

"Advancing Theranostics and Targeted Alpha Therapy with Astatine-211"

host : JP. POUGET (IRCM)

Prof. Tadashi Watabe is an Associate Professor at the University of Osaka, Japan. He is a board-certified nuclear medicine physician with extensive expertise in theranostics and targeted alpha therapy. He serves as the principal investigator (PI) of investigator-initiated clinical trials of astatine (²¹¹At)-based targeted alpha therapy. The Alpha-T1 trial, which investigated [²¹¹At]NaAt in patients with radioiodine-refractory thyroid cancer, has been completed. He is currently leading the ongoing first-in-human Alpha-PS1 trial, which uses [²¹¹At]PSMA-5 targeting prostate-specific membrane antigen (PSMA) in patients with castration-resistant prostate cancer (NCT06441994). He is also the PI of several clinical studies involving [¹⁸F]FAPI-74, [¹⁸F]FBPA, and [¹¹C]HCA2969. He has authored more than 170 peer-reviewed publications, with a primary research focus on the preclinical development of targeted alpha therapies using ²¹¹At and ²²⁵Ac, as well as theranostics related to FAPI, LAT1, and EphA2. He also serves as the Executive Congress Chair of the Theranostics World Congress 2027